This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease

Objectives: Although many depressed patients with Alzheimer disease (AD) are treated with antidepressants, the effect of such treatment on cognitive performance in these patients is not known. The authors report cognitive outcomes in patients with depression of AD (dAD) after a 24-week trial of sertraline or placebo.; Design: Placebo-controlled, randomized, double-blind trial.; Setting: Outpatient memory […]

Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer’s Disease Anti-inflammatory Prevention Trial

Objective: We examined the effects of non-steroidal anti-inflammatory drugs on cognitive decline as a function of phase of pre-clinical Alzheimer disease.; Methods: Given recent findings that cognitive decline accelerates as clinical diagnosis is approached, we used rate of decline as a proxy for phase of pre-clinical Alzheimer disease. We fit growth mixture models of Modified […]

Effect of second-generation antipsychotics on caregiver burden in Alzheimer’s disease

Background: Alzheimer’s disease (AD) imposes a severe burden upon patients and their caregivers. Severity of psychiatric symptoms and behavioral disturbances is an important determinant of caregivers’ experience of burden. These symptoms may be improved with atypical antipsychotic treatment.; Objective: Data from the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease (CATIE-AD) trial were used to evaluate […]

Extended results of the Alzheimer’s disease anti-inflammatory prevention trial

Background: Epidemiologic evidence suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) delay onset of Alzheimer’s dementia (AD), but randomized trials show no benefit from NSAIDs in patients with symptomatic AD. The Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) randomized 2,528 elderly persons to naproxen or celecoxib versus placebo for 2 years (standard deviation = 11 months) before treatments […]

Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD

Objective: The impact of the atypical antipsychotics olanzapine, quetiapine, and risperidone on cognition in patients with Alzheimer’s disease is unclear. The authors assessed the effects of time and treatment on neuropsychological functioning during the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease study (CATIE-AD).; Method: CATIE-AD included 421 outpatients with Alzheimer’s disease and psychosis or agitated/aggressive […]

Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer’s disease study ± 2 (DIADS-2)?

Objective: To determine if the effect of sertraline in the depression in Alzheimer’s disease study – 2 (DIADS-2) differed in subgroups of patients defined by baseline depression criteria.; Methods: DIADS-2 was a randomized, parallel, placebo-controlled, multicenter trial designed to evaluate the efficacy and safety of sertraline (target dose of 100 mg/day) for the treatment of depression […]

Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes

Background: Depression and antidepressant use are common in Alzheimer disease (AD), but the effect of antidepressant treatment for depression on longer term outcomes is unknown. The authors report the Week-24 outcomes of patients who participated in a 12-week efficacy study of sertraline for depression of AD.; Methods: One hundred thirty-one participants (sertraline = 67, placebo […]

Sertraline for the treatment of depression in Alzheimer disease

Objective: Depression is common in Alzheimer disease (AD), and antidepressants are commonly used for its treatment, however, evidence for antidepressant efficacy in this population is lacking. The authors conducted a multicenter, randomized, placebo-controlled trial titled “Depression in Alzheimer’s Disease-2” to assess the efficacy and tolerability of sertraline for depression in AD.; Methods: One hundred thirty-one […]

Metabolic changes associated with second-generation antipsychotic use in Alzheimer’s disease patients: the CATIE-AD study

Objective: The second-generation antipsychotics are associated with metabolic abnormalities in patients with schizophrenia. Elderly patients with Alzheimer’s disease are frequently treated with these antipsychotics, but limited data are available on their metabolic effects.; Method: The authors assessed 186 male and 235 female Alzheimer’s disease outpatients from the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease (CATIE-AD) […]

A multidimensional home-based care coordination intervention for elders with memory disorders: the maximizing independence at home (MIND) pilot randomized trial

Objectives: To assess whether a dementia care coordination intervention delays time to transition from home and reduces unmet needs in elders with memory disorders.; Design: 18-month randomized controlled trial of 303 community-living elders.; Setting: 28 postal code areas of Baltimore, MD.; Participants: Age 70+ years, with a cognitive disorder, community-living, English-speaking, and having a study […]